|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAM168B |
Gene summary for FAM168B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAM168B | Gene ID | 130074 |
| Gene name | family with sequence similarity 168 member B | |
| Gene Alias | MANI | |
| Cytomap | 2q21.1 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | A0A024QZ31 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 130074 | FAM168B | LZE2T | Human | Esophagus | ESCC | 2.82e-04 | 3.40e-01 | 0.082 |
| 130074 | FAM168B | LZE7T | Human | Esophagus | ESCC | 6.64e-03 | 2.40e-01 | 0.0667 |
| 130074 | FAM168B | LZE8T | Human | Esophagus | ESCC | 2.33e-02 | -5.36e-02 | 0.067 |
| 130074 | FAM168B | LZE22T | Human | Esophagus | ESCC | 1.41e-02 | 1.05e-01 | 0.068 |
| 130074 | FAM168B | LZE24T | Human | Esophagus | ESCC | 4.13e-09 | 9.73e-02 | 0.0596 |
| 130074 | FAM168B | LZE21T | Human | Esophagus | ESCC | 1.80e-03 | 3.15e-02 | 0.0655 |
| 130074 | FAM168B | P1T-E | Human | Esophagus | ESCC | 1.35e-06 | 1.90e-01 | 0.0875 |
| 130074 | FAM168B | P2T-E | Human | Esophagus | ESCC | 7.60e-22 | 3.23e-01 | 0.1177 |
| 130074 | FAM168B | P4T-E | Human | Esophagus | ESCC | 1.73e-18 | 5.39e-01 | 0.1323 |
| 130074 | FAM168B | P5T-E | Human | Esophagus | ESCC | 3.77e-13 | 2.92e-01 | 0.1327 |
| 130074 | FAM168B | P8T-E | Human | Esophagus | ESCC | 2.10e-16 | 1.77e-01 | 0.0889 |
| 130074 | FAM168B | P9T-E | Human | Esophagus | ESCC | 2.97e-09 | 1.03e-01 | 0.1131 |
| 130074 | FAM168B | P10T-E | Human | Esophagus | ESCC | 1.44e-19 | 4.71e-01 | 0.116 |
| 130074 | FAM168B | P11T-E | Human | Esophagus | ESCC | 5.10e-07 | 1.61e-01 | 0.1426 |
| 130074 | FAM168B | P12T-E | Human | Esophagus | ESCC | 7.72e-15 | 3.38e-01 | 0.1122 |
| 130074 | FAM168B | P15T-E | Human | Esophagus | ESCC | 8.50e-10 | 3.56e-01 | 0.1149 |
| 130074 | FAM168B | P16T-E | Human | Esophagus | ESCC | 4.45e-17 | 1.82e-01 | 0.1153 |
| 130074 | FAM168B | P17T-E | Human | Esophagus | ESCC | 7.31e-03 | 7.88e-02 | 0.1278 |
| 130074 | FAM168B | P19T-E | Human | Esophagus | ESCC | 2.91e-04 | 1.07e-01 | 0.1662 |
| 130074 | FAM168B | P20T-E | Human | Esophagus | ESCC | 1.57e-07 | 9.28e-02 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAM168B | SNV | Missense_Mutation | c.542G>A | p.Arg181Gln | p.R181Q | A1KXE4 | protein_coding | tolerated_low_confidence(0.06) | benign(0.084) | TCGA-BH-A1EX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| FAM168B | SNV | Missense_Mutation | novel | c.397C>A | p.Pro133Thr | p.P133T | A1KXE4 | protein_coding | deleterious_low_confidence(0.01) | benign(0.219) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| FAM168B | SNV | Missense_Mutation | c.163C>G | p.Pro55Ala | p.P55A | A1KXE4 | protein_coding | tolerated_low_confidence(0.51) | benign(0.05) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| FAM168B | SNV | Missense_Mutation | novel | c.206C>T | p.Ala69Val | p.A69V | A1KXE4 | protein_coding | deleterious_low_confidence(0) | benign(0.023) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FAM168B | SNV | Missense_Mutation | c.10N>A | p.Val4Ile | p.V4I | A1KXE4 | protein_coding | tolerated_low_confidence(0.12) | benign(0.007) | TCGA-CM-6164-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FAM168B | SNV | Missense_Mutation | c.511N>A | p.Ala171Thr | p.A171T | A1KXE4 | protein_coding | tolerated_low_confidence(0.09) | benign(0.025) | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| FAM168B | SNV | Missense_Mutation | rs376172440 | c.263G>A | p.Arg88Gln | p.R88Q | A1KXE4 | protein_coding | tolerated_low_confidence(0.06) | possibly_damaging(0.658) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| FAM168B | deletion | Frame_Shift_Del | c.413delC | p.Pro138LeufsTer25 | p.P138Lfs*25 | A1KXE4 | protein_coding | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| FAM168B | SNV | Missense_Mutation | novel | c.8N>A | p.Pro3His | p.P3H | A1KXE4 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.996) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| FAM168B | SNV | Missense_Mutation | rs376172440 | c.263N>A | p.Arg88Gln | p.R88Q | A1KXE4 | protein_coding | tolerated_low_confidence(0.06) | possibly_damaging(0.658) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |